The Technical Analyst
Clearside Biomedical Inc [CLSD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Clearside Biomedical Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.97% $1.260
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 94.15 mill |
| EPS: | -0.530 |
| P/E: | -2.38 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 74.72 mill |
| Avg Daily Volume: | 0.371 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.38 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.40x |
| Company: PE -2.38 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.083 - 1.437 ( +/- 14.05%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Gibney Anthony S | Buy | 93 290 | Common Stock |
| 2024-04-17 | Gibney Anthony S | Buy | 6 710 | Common Stock |
| 2024-04-15 | Gibney Anthony S | Buy | 45 000 | Stock Option (right to buy) |
| 2024-04-15 | Gibney Anthony S | Buy | 0 | |
| 2024-03-20 | Chong Ngai Hang Victor | Buy | 30 000 | Common Stock |
| INSIDER POWER |
|---|
| 66.43 |
| Last 97 transactions |
| Buy: 5 495 368 | Sell: 2 175 231 |
Forecast:
16:00 - $1.260
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.260
Forecast 2: 16:00 - $1.260
Forecast 3: 16:00 - $1.260
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.260 (-5.97% ) |
| Volume | 0.135 mill |
| Avg. Vol. | 0.371 mill |
| % of Avg. Vol | 36.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CLSD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CLSD
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Latest Press Releases
2024-04-16 07:05:00 - Press Release
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney To Its Board Of Directors
Alpharetta, ga., april 16, 2024 (globe newswire) -- clearside biomedical, inc. (nasdaq: clsd), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (scs®), announced today that anthony s.
2024-04-02 07:05:00 - Press Release
Clearside Biomedical To Participate In Fireside Chat At The 23rd Annual Needham Virtual Healthcare Conference
Alpharetta, ga., april 02, 2024 (globe newswire) -- clearside biomedical, inc. (nasdaq: clsd), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (scs®), announced today that george lasezkay, pharm.d., j.d., president and chief executive officer, and victor chong, m.d., mba, chief medical officer, will participate in a fireside chat at the 23r d annual needham virtual healthcare conference on wednesday, april 10, 2024, at 3:00 p.m. et.
2024-03-18 07:05:00 - Press Release
Clearside Biomedical Appoints Victor Chong, M.d., Mba As Chief Medical Officer
Industry veteran with extensive experience in retinal disease research and strong track record in advancing programs through clinical development industry veteran with extensive experience in retinal disease research and strong track record in advancing programs through clinical development
2024-03-12 16:05:00 - Press Release
Clearside Biomedical Announces Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
- phase 2b odyssey wet amd trial remains on track with topline data expected in q3 2024 - - partner programs continue to report positive clinical data utilizing scs microinjector ® - - strengthened capital position from registered direct equity offering and recent scs microinjector license agreement - - management to host webcast and conference call today at 4:30 p.m. et - alpharetta, ga.
2024-02-29 07:05:00 - Press Release
Clearside Biomedical To Report Fourth Quarter And Full Year 2023 Financial Results And Provide Corporate Update On Tuesday, March 12, 2024
Alpharetta, ga., feb. 29, 2024 (globe newswire) -- clearside biomedical, inc. (nasdaq: clsd), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (scs®), announced today that its fourth quarter and full year 2023 financial results will be reported on tuesday, march 12, 2024 after the close of the financial markets. management will host a webcast and conference call at 4:30 p.m. eastern time to discuss the results and provide a corporate update.
Latest News
2024-03-13 00:47:04 - Seeking Alpha
Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript
2024-02-29 07:05:00 - GlobeNewsWire
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
2024-02-25 13:37:41 - InvestorPlace
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
2023-10-31 07:05:00 - GlobeNewsWire
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023
ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2023 financial results will be reported on Monday, November 13, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
2023-10-26 00:24:10 - InvestorPlace
3 Cheap Stocks to Buy Under $1 in October 2023
For the extreme gambler who has done homework regarding risk and rewards, few thrills excite as much as cheap stocks to buy under $1. By logical deduction, of course, we're talking about penny stocks.
2023-09-19 07:05:00 - GlobeNewsWire
Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference
ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a panel discussion at the Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 2:10 p.m. ET in New York, NY.
2023-08-02 16:30:00 - GlobeNewsWire
Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023
ALPHARETTA, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will participate in the following investor conferences in August 2023:
2023-08-01 07:05:00 - GlobeNewsWire
Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023
ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2023 financial results will be reported on Monday, August 14, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
2023-07-11 16:05:00 - GlobeNewsWire
Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023
ALPHARETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., Clearside's President and Chief Executive Officer, will present at the SHARE™ Series Monday Management Update for investors on Monday, July 17, 2023, at 11:30 am ET.
2023-05-11 09:56:39 - Zacks Investment Research
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.13 per share a year ago.